RxDoctor Payments Data

Daniel Berg, MD

Internal Medicine · Saint Louis, MONPI 1013947555

Payments from drug & device makers

$671in general payments, 2019–2025

Across 28 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$205
  • Braeburn Inc.$159
  • Gilead$116
  • Novo Nordisk$52
  • Pfizer$43
  • AstraZeneca$25
  • plus $70 from 3 others

What the payments were for

  • Food & beverage$65698%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$3,419
Medicare patients
44
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide144$147,656
JardianceEmpagliflozin89$97,817
FarxigaDapagliflozin Propanediol114$92,779
OzempicSemaglutide84$86,957
EliquisApixaban84$76,426
MounjaroTirzepatide60$70,256
XareltoRivaroxaban36$44,083
JanuviaSitagliptin Phosphate36$32,052
EntrestoSacubitril/Valsartan31$26,068
SublocadeBuprenorphine12$24,648
LinzessLinaclotide39$24,368
Nurtec OdtRimegepant Sulfate11$22,308
RybelsusSemaglutide16$19,289
BelsomraSuvorexant31$12,936
Varenicline Tartrate60$12,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$22$217,912204 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$25$116,225181 claims
Novo NordiskOzempic, Rybelsus$52$106,246100 claims
PfizerEliquis, Nurtec Odt$43$98,73495 claims
Johnson & JohnsonXarelto$24$44,08336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →